Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | CBFB | Q13951 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADH5 | P11766 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10464389 | 0.90 | CYP19A1 (0.56) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL1901146 | 0.88 | CYP19A1 (0.55) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL9598976 | 0.79 | FBP1 (0.53) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL25597314 | 0.78 | CYP19A1 (0.57) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL21676341 | 0.78 | GRIK1 (0.52) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL4553354 | 0.77 | CA12 (0.51) | PDE3BPDE3ATBXAS1IDO1 | |
| SCHEMBL1081852 | 0.77 | PDE3B (0.46) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL4554379 | 0.77 | PDE3B (0.46) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL23839233 | 0.76 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL7349312 | 0.74 | PDE3B (0.50) | CYP19A1CYP11B1CYP11B2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CYP19A1 2161/4885CYP11B1 650/4885CYP11B2 470/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CYP19A1 2161/4885CYP11B1 650/4885CYP11B2 470/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | CYP19A1 2959/4885CYP11B1 2503/4885CYP11B2 2869/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CYP19A1 2161/4885CYP11B1 650/4885CYP11B2 470/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CYP19A1 2161/4885CYP11B1 650/4885CYP11B2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.